Big news, and exciting times!

QUINTA-ANALYTICA are very happy to announce new investment from renowned family equity firm BBA CapitalPartners.

As an established provider of R&D and regulatory services for the pharmaceutical, biotechnology, and generic drug industries, Quinta today announced an investment change as Genesis Capital Equity passed their majority stake to LVA Holding GmbH, a portfolio company of BBA Capital Partners (BBA).

With over two decades of development and innovation under its belt, Quinta is a provider of services to the global pharmaceutical market and offers a wide portfolio of services, a diversified client portfolio, and presence in Europe and North America.

Roman Grunt, CEO, and Chairman of the Board of Directors of Quinta stated: “This move is another step for Quinta and its people on our growth path. Genesis supported our development projects and together we managed to overcome difficult years. I sincerely thank Jan Tauber and the entire Genesis team for this”.

He continued that “We are now looking forward to moving ahead with our new partner. We knew this change must come and I am delighted that it is BBA. Today we have a chance to not only keep Quinta’s essence, but with the network and financial support of our new partner we will grow further and play a leading role in building the pharma division within BBA’s portfolio”.

Concluding with recognition of his team he added “I can also not thank our management team enough, including CCO Jiri Raska, and CSO Marcela Písačková, as well as all of our employees and partners for where we are today. With this wind in our back, we strive to go further and provide the best possible service to our customers“.

Also commenting on the move, Felix Burgdorf, Managing Director and Co-Founder of BBA, stated: “Quinta is a leading independent partner for pharmaceutical companies, ensuring pharmaceutical drugs are safely and rapidly brought to those who need them. Their focus on its customers, high quality, scientific excellence, and flexibility differentiates it in the market. We are excited to partner with the top management team and employees to continue to be a reliable partner as well as to sustainably and responsibly develop further to the benefit of end-consumers.”

Learn more about Quinta-Analytica by getting in touch with us, and read the official press release at

Additional News

  • 18 July 2023

    Challenges of a large-scale study of breast cancer

    Our bioanalytical experts and a high-profile client team up for the development of a new therapy for breast cancer.

  • 29 June 2023

    EU funding for Quinta-Analytica laboratory in Brno (CZ) was succesfully completed.

    After two years, the project to finance new equipment for the Quinta-Analytica laboratory in Brno was successfully completed. The investment from European Regional Development Fund was used in this project.

  • 22 June 2023

    Quinta Analytica Partners with EvidentIQ to Enhance Efficiency of Phase 1 Studies

    EvidentIQ partners with Quinta-Analytica to enhance Phase 1 study efficiency